Tumor cells presenting the patient-specific neoantigen peptide on HLA-A*02:01 are recognized by the infused neoantigen-specific CD8+ T cells via their endogenous TCRs, leading to perforin/granzyme-mediated cytolysis (with possible Fas–FasL apoptosis).